In a mouse model of MASH, supplementation with deoxycholic acid (DCA) enhanced farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) signaling, improving glucose tolerance and insulin resistance, and reducing liver steatosis (Oseini and Sanyal, 2017). This evidence concerns the gene GPBAR1 and fatty liver disease.